GlassScriptPhysician profile
Marlen Padron
NPI 1275078610
$4,317.42
in general payments reported to CMS, 2019-2025
28 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 94% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.56 · 2022: $101 · 2023: $772 · 2024: $1,363 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,144.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.85 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $521.01 | 2023-2025 | |
| Atricure, INC. | $455.03 | 2023-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Amgen INC. | $441.05 | 2021-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $287.79 | 2023-2025 | Farxiga, Wainua |
| Scpharmaceuticals INC. | $240.90 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.13 | 2022-2023 | Lifevest |
| Boston Scientific Corporation | $207.22 | 2021-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $165.17 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $157.09 | 2024-2025 | Camzyos |
| Insmed, INC. | $138.89 | 2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $121.13 | 2025 | Nuzyra |
| Alnylam Pharmaceuticals INC. | $114.07 | 2024-2025 | Onpattro, Amvuttra |
| Lexicon Pharmaceuticals, INC. | $101.93 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $99.97 | 2024 | Arcalyst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $67.32 | 2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $63.55 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $61.53 | 2024-2025 | Verquvo |
| Impulse Dynamics (USA) INC. | $55.10 | 2023-2024 | Optimizer, Optimizer |
| Edwards Lifesciences Corporation | $41.17 | 2023 | |
| Bridgebio Pharma, INC. | $37.13 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $31.83 | 2025 | Arexvy, Shingrix |
| Kiniksa Pharmaceuticals, LTD. | $24.67 | 2023 | Arcalyst |
| Abiomed | $22.63 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $22.05 | 2024 | Opsumit, Uptravi |
| Abbott Laboratories | $19.98 | 2021 | |
| Esperion Therapeutics, INC. | $18.12 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $16.11 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlen Padron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.